Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea · Delayed Price · Currency is KRW 6,980.00
-210.00 (-2.92%)
At close: Sep 16, 2026
KOSDAQ:318160 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 60,901 | 51,066 | 28,419 | 27,324 | 27,545 | 35,161 |
Other Revenue | -0 | -0 | -0 | - | - | - |
| 60,901 | 51,066 | 28,419 | 27,324 | 27,545 | 35,161 | |
Revenue Growth | 61.93% | 79.69% | 4.00% | -0.80% | -21.66% | 22.99% |
Cost of Revenue | 40,584 | 32,221 | 19,374 | 19,596 | 19,902 | 24,935 |
Gross Profit | 20,317 | 18,845 | 9,045 | 7,729 | 7,643 | 10,225 |
Selling, General & Admin | 8,786 | 7,955 | 4,099 | 3,268 | 3,000 | 3,212 |
Research & Development | 848.86 | 684.43 | 486.14 | 656.59 | 742.09 | 718.36 |
Amortization of Goodwill & Intangibles | 63.37 | 45.04 | 53.37 | 48.98 | 41.04 | 25.87 |
Operating Expenses | 10,541 | 9,528 | 5,008 | 4,579 | 4,108 | 4,616 |
Operating Income | 9,776 | 9,317 | 4,037 | 3,149 | 3,535 | 5,610 |
Interest Expense | -898.55 | -319.51 | -411.21 | -489.03 | -454.76 | -611.9 |
Interest & Investment Income | 324.9 | 253.45 | 519.2 | 340.99 | 103.29 | 114.53 |
Earnings From Equity Investments | - | - | - | - | - | 30.18 |
Currency Exchange Gain (Loss) | 1,745 | -609.81 | 971.21 | -257.14 | 754.46 | 1,227 |
Other Non Operating Income (Expenses) | -17.58 | 153.35 | 57.39 | -2,975 | -377.89 | 11.75 |
EBT Excluding Unusual Items | 10,930 | 8,795 | 5,173 | -231.01 | 3,560 | 6,381 |
Gain (Loss) on Sale of Investments | -20.04 | 6.81 | 5 | - | - | -1,500 |
Gain (Loss) on Sale of Assets | 22.95 | 181.58 | 12.55 | -218.15 | -19.17 | -93.86 |
Asset Writedown | - | - | - | -362.66 | - | -308.07 |
Pretax Income | 10,933 | 8,983 | 5,191 | -811.82 | 3,541 | 4,479 |
Income Tax Expense | 475.14 | 287.97 | 812.16 | 1,045 | 650.94 | 1,367 |
Earnings From Continuing Operations | 10,458 | 8,695 | 4,379 | -1,857 | 2,890 | 3,113 |
Minority Interest in Earnings | 108.19 | 26.01 | - | - | - | 18.85 |
Net Income | 10,566 | 8,721 | 4,379 | -1,857 | 2,890 | 3,131 |
Net Income to Common | 10,566 | 8,721 | 4,379 | -1,857 | 2,890 | 3,131 |
Net Income Growth | 78.81% | 99.17% | - | - | -7.71% | -17.07% |
Shares Outstanding (Basic) | 8 | 8 | 9 | 8 | 7 | 7 |
Shares Outstanding (Diluted) | 8 | 8 | 9 | 8 | 7 | 8 |
Shares Change | -3.63% | -8.00% | 5.59% | 20.68% | -11.32% | -1.95% |
EPS (Basic) | 1272.28 | 1062.52 | 490.80 | -219.80 | 412.78 | 447.27 |
EPS (Diluted) | 1272.28 | 1062.52 | 490.80 | -220.00 | 412.78 | 396.66 |
EPS Growth | 85.55% | 116.49% | - | - | 4.06% | -23.72% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6,415 | -5,151 | 7,247 | 1,131 | 77.49 | 3,889 |
Free Cash Flow Per Share | -772.41 | -627.58 | 812.26 | 133.91 | 11.07 | 492.62 |
Gross Margin | 33.36% | 36.90% | 31.83% | 28.29% | 27.75% | 29.08% |
Operating Margin | 16.05% | 18.25% | 14.21% | 11.53% | 12.83% | 15.96% |
Profit Margin | 17.35% | 17.08% | 15.41% | -6.80% | 10.49% | 8.91% |
Free Cash Flow Margin | -10.53% | -10.09% | 25.50% | 4.14% | 0.28% | 11.06% |
EBITDA | 12,804 | 11,752 | 5,943 | 4,953 | 5,396 | 7,149 |
EBITDA Margin | 21.02% | 23.01% | 20.91% | 18.13% | 19.59% | 20.33% |
D&A For EBITDA | 3,028 | 2,434 | 1,906 | 1,803 | 1,861 | 1,539 |
EBIT | 9,776 | 9,317 | 4,037 | 3,149 | 3,535 | 5,610 |
EBIT Margin | 16.05% | 18.25% | 14.21% | 11.53% | 12.83% | 15.96% |
Effective Tax Rate | 4.35% | 3.21% | 15.65% | - | 18.38% | 30.51% |
Advertising Expenses | - | - | - | - | - | 0.8 |